KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET‐expressing tumor cells

The MET receptor tyrosine kinase is often deregulated in human cancers and several MET inhibitors are evaluated in clinical trials. Similarly to EGFR, MET signals through the RAS‐RAF‐ERK/MAPK pathway which plays key roles in cell proliferation and survival. Mutations of genes encoding for RAS protei...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Mol Oncol
Prif Awduron: Leiser, Dominic, Medová, Michaela, Mikami, Kei, Nisa, Lluís, Stroka, Deborah, Blaukat, Andree, Bladt, Friedhelm, Aebersold, Daniel M., Zimmer, Yitzhak
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2015
Pynciau:
Research Papers
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528816/
https://ncbi.nlm.nih.gov/pubmed/25933688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2015.04.001
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg